Finance

Lists
MLTX:NASDAQ
MoonLake Immunotherapeutics
$16.50
-4.24%
(-0.73) 1D
$16.55
+0.30% (+0.050)
After hours
Closed: Aug 13, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLTX...
Open
$17.64
High
$17.73
Low
$16.47
Mkt. cap
1.40B
Avg. vol.
1.26M
Volume
1.34M
52-wk high
$62.75
52-wk low
$5.95
EPS
-$3.83
Beta
1.07
Shares outstanding
85.11M
No. of employees
130
Open
$17.64
High
$17.73
Low
$16.47
Mkt. cap
1.40B
Avg. vol.
1.26M
Volume
1.34M
52-wk high
$62.75
52-wk low
$5.95
EPS
-$3.83
Beta
1.07
Shares outstanding
85.11M
No. of employees
130
News stories
From web sources and news partners
About MoonLake Immunotherapeutics
CEO-
Employees130
Founded2020
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitemoonlaketx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MLTX in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MLTX in the last 3 months.
Highest
Current $16.50
$70.00 (+324.24%)
Average
$38.00 (+130.30%)
Lowest
$17.00 (+3.03%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Maintained
$50.00
+203%
08/13/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$40.00
+142.4%
08/10/2026
Julian Harrison
BTIG
Buy
Maintained
$30.00
+81.8%
08/10/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/10/2026
Serge Belanger
Needham
Buy
Maintained
$30.00
+81.8%
08/10/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$33.00
+100%
08/10/2026
Yun Zhong
Wedbush
Buy
Maintained
$34.00
+106.1%
08/10/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$17.00
+3%
08/10/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$70.00
+324.2%
06/22/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$12.00
-27.3%
05/11/2026
Andy Chen
Wolfe Research
Buy
Upgraded
$24.00
+45.5%
03/23/2026
Samantha Semenkow
Citi
Sell
Maintained
$6.00
-63.6%
03/20/2026
Qize Ding
Rothschild & Co Redburn
Buy
Upgraded
$40.00
+142.4%
03/19/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
$19.00
+15.2%
03/01/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$35.00
+112.1%
02/24/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$20.00
+21.2%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
49.76M
60.64M
56.01M
54.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.94M
10.80M
9.21M
15.51M
Operating expense
60.70M
71.43M
65.22M
70.02M
Total operating expenses
60.70M
71.43M
65.22M
70.02M
Operating income
-60.70M
-71.43M
-65.22M
-70.02M
Other non operating income
6.40M
4.32M
3.92M
3.15M
EBT including unusual items
-55.96M
-70.58M
-62.77M
-69.08M
EBT excluding unusual items
-55.96M
-70.58M
-62.77M
-69.08M
Income tax expense
95.00K
115.00K
248.00K
622.00K
Effective tax rate
-0.17%
-0.16%
-0.40%
-0.90%
Other operating expenses
-
-
-
-
Net income
-55.22M
-69.73M
-62.43M
-69.71M
Net profit margin
-
-
-
-
Earnings per share
-0.87
-1.10
-0.92
-0.98
Interest and investment income
-
-
-
-
Interest expense
-2.04M
-3.20M
-1.99M
-2.27M
Net interest expenses
-2.04M
-3.20M
-1.99M
-2.27M
Depreciation and amortization charges
-
-
-
-
EBITDA
-59.96M
-70.69M
-64.47M
-69.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps